Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, Open Label, Multicenter Study of the Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, Administered to Patients With Advanced Malignancies

Next Previous
Trial Profile

A Phase Ia/Ib, Open Label, Multicenter Study of the Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, Administered to Patients With Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IBI 389 (Primary) ; Sintilimab
  • Indications Adenocarcinoma; Gastric cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Innovent Biologics

Most Recent Events

  • 04 Jun 2024 Preliminary results (As of January 9, 2024, N=114) assessing safety and efficacy of IBI389 in patients (pts) with advanced solid tumors, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 04 Jun 2024 Results(as of January 9, 2024, n= 64) assessing safety and efficacy presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 02 Jun 2024 According to an Innovent Biologics media release, data from this trial were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top